Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms

Cell Rep Med. 2024 Sep 17;5(9):101697. doi: 10.1016/j.xcrm.2024.101697. Epub 2024 Aug 22.

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors. In this study, we develop a clinically useful computational pathology platform for NSCLC that can be a foundation for multiple downstream applications and provide immediate value for patient care optimization and individualization. We train the primary multi-class tissue segmentation algorithm on a substantial, high-quality, manually annotated dataset of whole-slide images with lung adenocarcinoma and squamous cell carcinomas. We investigate two downstream applications. NSCLC subtyping algorithm is trained and validated using a large, multi-institutional (n = 6), multi-scanner (n = 5), international cohort of NSCLC cases (slides/patients 4,097/1,527). Moreover, we develop four AI-derived, fully explainable, quantitative, prognostic parameters (based on tertiary lymphoid structure and necrosis assessment) and validate them for different clinical endpoints. The computational platform enables the high-precision, quantitative analysis of H&E-stained slides. The developed prognostic parameters facilitate robust and independent risk stratification of patients with NSCLC.

Keywords: AI; NSCLC; algorithm; lung cancer; prognosis; subtyping.

Publication types

  • Validation Study

MeSH terms

  • Algorithms*
  • Carcinoma, Non-Small-Cell Lung* / diagnosis
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / pathology
  • Female
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / pathology
  • Male
  • Prognosis